Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 98-1480821 (State ...

Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in fourth quarter of 2024 Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors Strong financial position with cash balance of $927.1 million expected to fund projected operation ...

Structure Therapeutics' lead product candidate is GSBR-1290, a highly selective oral GLP-1 receptor agonist, which is being evaluated in multiple mid-stage studies for treating healthy overweight or obese individuals. The Zacks Consensus Estimate is currently pegged at a loss of 23 cents per share. Let's see how things might have shaped up for the upcoming quarterly release. The company plans to file an investigational new drug application to the FDA in the third quarter of 2024 to begin the phase IIb obesi ...

There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow. In fact, according to Grand View Research, biotech could be worth about $3.88 trillion by 2030. After all, there's always going to be a need for biotech. Fueling even more upside is artificial intelligence, which may be able to create new drugs that can treat untreatable issues. There's even newer innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, gene editing ...

Structure Therapeutics (GPCR 0.84%) and Novo Nordisk (NVO -0.68%) have one big thing in common: the desire to compete in the bustling market for obesity therapies. While the pre-revenue biotech is still a fledgling in the midst of its attempt to develop its first approved medicine, some recently released data suggests that Novo Nordisk might want to keep an eye out. This market won't be winner-take-all That's a tall order, as Novo's trailing-12-month revenue is $35.5 billion, and the cardiometabolic segment ...

The capsule-to-tablet PK study was designed to evaluate the tolerability, safety and pharmacokinetics of a new tablet formulation of GSBR-1290 in the given patient population. Data from the capsule-to-tablet PK study showed that treatment with the tablet formulation of GSBR-1290 led to a placebo-adjusted mean weight loss of up to 6.9% at 12 weeks. Image Source: Zacks Investment Research Obesity has become a global health problem as it can cause heart disease, diabetes and stroke, leading to an exponential i ...

Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. Shares of Structure Therapeutics (GPCR -0.30%) shot up more than 50% during the first week of June. The stock market is responding to a positive readout for an experimental weight-management drug the company is working on. Structure Therapeutics is a clinical-stage drugmaker developing an orally available therapy, called GSBR-1290. Structure's lead candidate works like semaglutide, the ...

About Structure Therapeutics Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities and BMO Capital Markets acted as joint book-running managers for the offering. Investors: Danielle Keatley Structure Therapeutics Inc. ir@structuretx.com Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on June 5, 2024. Copies of the registration statements can be accessed through the SEC's web ...

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,360,045 addition ...

SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offer ...